Mutual Funds › MFIC › Index Fund › ICICI Prudential Nifty Pharma Index Fund

ICICI Prudential Nifty Pharma Index Fund

ICICI Prudential Mutual Fund · Index Fund · Regular plan, growth option

NAV (₹), 1 Oct 2026
19.8872
1-day change
-0.48%
1Y return
20.4%
3Y CAGR
18.8%
5Y CAGR
n/a
Max drawdown, 5Y
n/a
NAV history month-end NAV, ₹ · 15 Dec 2022 to 1 Oct 2026
9.114.820.62023202420252026
Returns vs Index Fund median (276 schemes) and “Sector: Healthcare & pharma” median (5)
PeriodSchemeCategory medianSector: Healthcare & pharma median
1 month-1.9%-6.5%-2.4%
3 months4.4%-5.3%2.1%
6 months19.3%5.2%19.4%
Year to date15.5%-7.2%15.5%
1 year20.4%-3.6%15.8%
3 years (CAGR)18.8%9.0%18.8%
5 years (CAGR)n/a6.8%n/a
7 years (CAGR)n/a10.9%n/a
10 years (CAGR)n/a10.5%n/a
Since first NAV (CAGR)20.0%––

“Sector: Healthcare & pharma” is MFIC's grouping of Index Fund schemes by the theme or index in their names, not an AMFI category.

Rolling returns every business-day start date
MeasureSchemeCategory median
1Y rolling median15.0%6.8%
3Y rolling median21.0%16.2%
3Y rolling worst18.1%8.4%
3Y periods positive100%100%
3Y periods ahead of benchmarkn/an/a
5Y rolling mediann/a12.9%
5Y rolling worstn/a5.9%
5Y periods ahead of benchmarkn/an/a

Benchmark: none available in MFIC's free data for this category.

Risk 36 months, monthly returns, Rf 6.5%
MeasureSchemeCategory median
Standard deviation (ann.)15.7%17.6%
Sharpe ratio0.910.22
Sortino ratio1.560.31
Betan/an/a
Alpha (ann.)n/an/a
Upside capturen/an/a
Downside capturen/an/a
Drawdowns peak-to-trough falls in NAV
MeasureSchemeCategory median
Maximum drawdown, full history−16.8%−19.1%
Maximum drawdown, last 10Yn/a−38.1%
Maximum drawdown, last 5Yn/a−17.9%
Current drawdown−3.3%−11.5%
Recovery time of worst fall432 days–

Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.

Market context from Integrato Market Intelligence

This scheme aim to track one of the markets below, so its level, valuation and recent path are the main drivers of returns.

26,311.55 −0.48%
NSE close, 1 Oct 2026
  • P/E 40.7: higher than 94% of days since 2023 (median 34.7)
  • 1Y +21.5% · 3Y +19.9% p.a. · 5Y +13.1% p.a. (index fund NAV, after costs)
  • −3.2% from its 52-week high
16,095.55 −0.26%
NSE close, 1 Oct 2026
  • P/E 41.9: higher than 77% of days since 2023 (median 39.2)
  • 1Y +12.4% · 3Y n/a p.a. · 5Y n/a p.a. (index fund NAV, after costs)
  • −5.0% from its 52-week high (proxy NAV)

Index levels and P/E: NSE daily index closing values; gold and silver: IBJA rates; returns: growth NAV of an index fund or ETF tracking the market (AMFI), so they are after that fund's costs. Context only: a market's level or valuation does not tell you how any scheme will perform. Explore all markets.

Direct or Regular for this scheme?

The Regular plan's expense ratio is 1.18% a year and the Direct plan's 0.51%, a gap of 0.67%; over the last 3 years the Direct plan returned 0.74 percentage points a year more. On a ₹25,000 monthly SIP for 20 years (illustration at 12% a year before costs) the gap adds up to about ₹16,69,441.

With the Regular plan, that cost pays a distributor to help you plan, choose and review funds, and stay invested when markets fall. Whether it is worth it depends on how much of that you will do yourself.

TER: AMFI TER disclosure. Returns: AMFI NAVs. Illustration, not a guaranteed saving or return.

Fund managers and scheme facts Scheme Summary Document via AMFI
Fund managerRoleManaging since
Nishit PatelComanage14 Dec 2022
Ashwini BharuchaComanage18 Dec 2024
Venus Ahuja1 Nov 2025
Objective: The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Stated asset allocation: • Equity and Equity related securities of companies constituting the underlying index (Nifty Pharma Index) = 95% - 100% • Money Market instruments including TREPs* and Units of debt schemes# = 0% - 5%
Benchmark (tier 1): Nifty Pharma TRI
Minimum application: Rs. 1000
Allotment date: 14 Dec 2022

Documents: Scheme Information Document · Scheme Summary Document. Read the scheme documents before investing.

Cost, size and riskometer as disclosed to AMFI
MeasureSchemeCategory median
Expense ratio (TER), Regular plan1.18%1.10%
AUM, whole scheme (₹ crore)163159
RiskometerVery High–

TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.

Official benchmark and category consistency
MeasureSchemeBenchmark / category
Return, 1 year (AMFI)22.6%24.0% TRI
Return, 3 years (AMFI)19.0%20.4% TRI

Official benchmark: Nifty Pharma TRI (total return index, as published by AMFI). Category consistency: last 10 years of month-ends, Index Fund Regular plans; how it is calculated.

Calendar-year returns NAV change from 31 Dec to 31 Dec
YearSchemeBenchmarkDifference
2026 YTD15.5%n/a–
2025-3.2%n/a–
202438.0%n/a–
202331.9%n/a–

No free benchmark proxy for this category. The first year starts from the first 31 December in the scheme's history.

Monthly SIP of ₹10,000 first business day of each month, ending 1 Oct 2026
PeriodInvestedValueXIRR
1 year₹1,20,000₹1,34,47023.1%
3 years₹3,60,000₹4,49,83015.0%

Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.

Scheme facts
AMC: ICICI Prudential Mutual Fund
Category: Index Fund
Plan / option: Regular · Growth
AMFI scheme code: 150929
ISIN: INF109KC18L6
First NAV in MFIC data: 15 Dec 2022
History: 3.8 years
Portfolio holdings: see the scheme's monthly portfolio disclosure on the fund house website
Schemes that behaved similarly correlation of monthly returns, last 5 years
Questions about ICICI Prudential Nifty Pharma Index Fund
What is the latest NAV of ICICI Prudential Nifty Pharma Index Fund?
The NAV of the Regular plan (growth option) was ₹19.8872 on 1 Oct 2026, as published by AMFI.
Which category is ICICI Prudential Nifty Pharma Index Fund in?
It is classified as Index Fund in AMFI's daily NAV file; a Index Fund scheme passively tracks a stated index. MFIC compares it with 276 Index Fund schemes (Regular plans).
What returns has ICICI Prudential Nifty Pharma Index Fund delivered?
Over one year the NAV changed by 20.4%. The 3-year CAGR is 18.8% (category median 9.0%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
How consistent have its 3-year returns been?
Measuring a 3-year CAGR from every business day in its history, the median was 21.0%, the lowest was 18.1%, and 100% of 3-year periods ended with a gain.
What was the largest fall in ICICI Prudential Nifty Pharma Index Fund's NAV?
The largest peak-to-trough fall in its available history was 16.8%.
How volatile is ICICI Prudential Nifty Pharma Index Fund?
Its annualised standard deviation of monthly returns over the last 36 months is 15.7%, which is below the Index Fund category median of 17.6%.
What would a monthly SIP in ICICI Prudential Nifty Pharma Index Fund have grown to?
A SIP of ₹10,000 on the first business day of each month for the last 3 years (36 instalments, ₹3,60,000 invested) would have been worth about ₹4,49,830 on 1 Oct 2026, an annualised return (XIRR) of 15.0%. This uses the Regular plan's NAVs, ignores taxes and exit loads, and past performance may or may not be sustained in future.
What is the expense ratio (TER) of ICICI Prudential Nifty Pharma Index Fund?
The total expense ratio of the Regular plan is 1.18% a year, as disclosed to AMFI (median of Index Fund Regular plans: 1.10%). It is already deducted from the NAV, so every return shown is after expenses.
How large is ICICI Prudential Nifty Pharma Index Fund?
Assets under management of the whole scheme were ₹163 crore on 30 Sep 2026, as published by AMFI.
What is the riskometer level of ICICI Prudential Nifty Pharma Index Fund?
AMFI lists the scheme's riskometer as “Very High”, and its benchmark's as “Very High”. The riskometer is a label of potential risk set under SEBI rules, not a forecast.
What is the benchmark of ICICI Prudential Nifty Pharma Index Fund and how has it compared?
Its official benchmark is the Nifty Pharma TRI. Over 3 years AMFI reports a return of 19.0% for this plan against 20.4% for the benchmark total return index. Past performance does not indicate future results.
Who manages ICICI Prudential Nifty Pharma Index Fund?
According to its Scheme Summary Document, ICICI Prudential Nifty Pharma Index Fund is managed by Nishit Patel (since 14 Dec 2022), Ashwini Bharucha (since 18 Dec 2024), Venus Ahuja (since 1 Nov 2025).
What is the minimum investment in ICICI Prudential Nifty Pharma Index Fund?
The minimum application amount is Rs. 1000.
What is the difference between the Direct and Regular plans?
Both plans hold the same portfolio; the Regular plan includes distribution costs in its expense ratio. Over one year the Direct plan's NAV changed by 21.2% and the Regular plan's by 20.4%. The Regular plan includes the services of a distributor.
Reviewing your own mutual fund portfolio?
Integrato's team can walk you through how your current schemes have behaved, using the same data shown here. Integrato is an AMFI-registered Mutual Fund Distributor.
Follow ICICI Prudential Nifty Pharma Index Fund by email

Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.

We email a confirmation link first. Integrato is an AMFI-registered Mutual Fund Distributor (ARN-173155); these emails are information, not recommendations.

Data & disclosure. Source: AMFI daily NAV file and historical NAVs via mfapi.in; calculations by MFIC, as of 1 Oct 2026. Category medians use Regular plans in the same AMFI category. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance may or may not be sustained in future. This page is for research and education only and is not investment advice or a recommendation to buy, sell or hold any scheme. Integrato Financial Services Pvt. Ltd. is an AMFI-registered Mutual Fund Distributor (ARN-173155). Methodology.